In Silico analysis to identify potential inhibitors of N-Myristoyltransferase in Leishmania donovani through drug Repurposing
DOI:
https://doi.org/10.55627/zoobotanica.002.03.0998Keywords:
Visceral leishmaniasis, Leishmania donovani, kalazar, drug dockingAbstract
Visceral leishmaniasis (VL) or Kalazar, is a vector-borne parasitic disease caused by Leishmania donovani, which is spread through the bite of sand flies from infected animals or humans. The disease continues to be a major health concern due to limited treatment options. One of the key proteins involved in the viability of the parasite is N-myristoyltransferase (NMT), making it a prominent target for new drug development. Development of new drugs require a lot of resources and time. The current study was designed to find potential L. donovani NMT inhibitors from the existing drugs used for other disease through insilico studies. To identify potential inhibitors for NMT, the 3D structure of the L. donovani NMT was obtained from the protein data bank. More than one hundred and fifty potential FDA approved drugs were retrieved from chemspider. These drugs were docked using the online PatchDock server, selecting the top results. The interactions were visualized using GS Viewer and LIGPLOT. The interactions formed include hydrogen bonding, covalent interactions, and hydrophobic interactions with the key active site residues of the target, suggesting at potential mechanism of inhibition. The present study successfully identified promising potential inhibitors of L. donovani NMT. The drugs that showed maximum interactions includes Clarithromycin, Amoxicillin, Bacampicillin and Ciprofloxacin which could serve as candidates for experimental testing in future studies. The findings of the current study lay the foundation for developing new treatments for visceral leishmaniasis.
References
Arsic, B., Novak, P., Kragol, G., Barber, J., Rimoli, M. G., & Sodano, F. (2018). Macrolides: Properties, Synthesis and Applications. Walter de Gruyter GmbH & Co KG. DOI: 10.1515/9783110515756.
Ayers, M. (2012). ChemSpider: the free chemical database. Reference Reviews, 26(7), 45-46. DOI:10.1108/09504121211271059.
Baig, A. M., Suo, X., & Liu, D. (2024). Pathogenesis of protozoan infections. In Molecular Medical Microbiology (pp. 2921-2940). Academic Press.
Bora, K., Sarma, M., Kanaujia, S. P., & Dubey, V. K. (2024). Development of novel dual-target drugs against visceral leishmaniasis and combinational study with miltefosine. Free Radical Biology and Medicine, 225, 275-285. DOI: 10.1016/j.freeradbiomed.2024.10.257.
Brand, S., Cleghorn, L. A., McElroy, S. P., Robinson, D. A., Smith, V. C., Hallyburton, I., Harrison, J. R., Norcross, N. R., Spinks, D., & Bayliss, T. (2011). Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. Journal of Medicinal Chemistry, 55(1), 140-152. https://doi.org/10.1021/jm201091t.
Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Di Costanzo, L., Christie, C., Dalenberg, K., Duarte, J. M., & Dutta, S. (2019). RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Research, 47(D1), D464-D474. DOI: 10.1093/nar/gky1004.
Copeland, R. A. (2013). Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. John Wiley & Sons.
Dabhi, M., Patel, R., Shah, V., Soni, R., Saraf, M., Rawal, R., & Goswami, D. (2024). Penicillin-binding proteins: the master builders and breakers of bacterial cell walls and its interaction with β-lactam antibiotics. Journal of Proteins and Proteomics, 15(2), 215-232. DOI: 10.1007/s42485-024-00135-x
dos Santos Nascimento, I. J., Cavalcanti, M. d. A. T., & de Moura, R. O. (2023). Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases. European Journal of Medicinal Chemistry, 258, 115550. DOI: 10.1016/j.ejmech.2023.115550.
França, S. B., da Silva, J. E., Silva, L. R., Padilha, E. K., Almeida-Souza, F., Barbosa, L. S., Calabrese, K. S., Lima, D. J., & da Silva-Júnior, E. F. (2024). Development of α-acyloxycarboxamides targeting Leishmania amazonensis parasite. New Journal of Chemistry, 48(43), 18618-18630. https://doi.org/10.1039/D4NJ02541E.
Gayaparsad, M. (2022). Drug repurposing: new tricks for old drugs. Southern African Journal of Anaesthesia and Analgesia, S127-S131. https://doi.org/10.36303/SAJAA.2022.28.5.2904.
Gelb, M. H., Van Voorhis, W. C., Buckner, F. S., Yokoyama, K., Eastman, R., Carpenter, E. P., Panethymitaki, C., Brown, K. A., & Smith, D. F. (2003). Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology, 126(2), 155-163.
Gunn, A., & Pitt, S. J. (2022). Parasitology: an integrated approach. John Wiley & Sons.
Jandl, B., Zheng, R., Muttenthaler, M., & Baell, J. (2024). Novel Diacyl-hydrazide Compounds as Potential Therapeutics for Visceral Leishmaniasis. ACS Omega, 9(35), 37170-37182. DOI: 10.1021/acsomega.4c04517.
Jejurikar, B. L., & Rohane, S. H. (2021). Drug designing in discovery studio. Asian Journal of Research in Chemistry, 14(2), 135-138. https://doi.org/10.5958/0974-4150.2021.00025.0
Kamhawi, S. (2006). Phlebotomine sand flies and Leishmania parasites: friends or foes? Trends in Parasitology, 22(9), 439-445. DOI: 10.1016/j.pt.2006.06.012.
Karunarathna, I., Hapuarachchi, T., Gunasena, P., & Gunathilake, S. (2024). Comprehensive review of Amoxicillin: Indications, mechanism of action, and clinical application. In: ResearchGate. https://www. researchgate. net/publication/383231049.
Kaur, S. P., Rao, R., & Nanda, S. (2011). Amoxicillin: a broad spectrum antibiotic. Int J Pharm Pharm Sci, 3(3), 30-37.
Killick-Kendrick, R. (1999). The biology and control of phlebotomine sand flies. Clinics in Dermatology, 17(3), 279-289. DOI: 10.1016/s0738-081x(99)00046-2.
LeBel, M. (1988). Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 8(1), 3-30. DOI: 10.1002/j.1875-9114.
Lee, J. W. (2024). Clarithromycin. In Helicobacter pylori (pp. 485-495). Springer.
Matos, A., Viçosa, A., Ré, M.-I., Ricci-Júnior, E., & Holandino, C. (2020). A review of current treatments strategies based on paromomycin for leishmaniasis. Journal of Drug Delivery Science and Technology, 57, 101664.
Mentis, A. F. A., Hernandez, H. W., & Kaitin, K. I. (2024). Drug repurposing for neglected and zoonotic diseases. Trends in Pharmacological Sciences, 45(12), 1100-1103. DOI: 10.1016/j.tips.2024.10.012.
Mohanty, M., & Mohanty, P. S. (2023). Molecular docking in organic, inorganic, and hybrid systems: a tutorial review. Monatshefte für Chemie-Chemical Monthly, 154(7), 683-707. DOI: 10.1007/s00706-023-03076-1.
Nico, D., Conde, L., & Palatnik de Sousa, C. B. (2021). Classical and modern drug treatments for leishmaniasis. Antiprotozoal Drug Development and Delivery, 1-21. https://doi.org/10.1007/7355_2021_132.
Pinzi, L., Bisi, N., & Rastelli, G. (2024). How drug repurposing can advance drug discovery: challenges and opportunities. Frontiers in Drug Discovery, 4, 1460100. https://doi.org/10.3389/fddsv.2024.1460100.
Ready, P. D. (2014). Epidemiology of visceral leishmaniasis. Clinical Epidemiology, 147-154. DOI: 10.2147/CLEP.S44267.
Ribeiro, J. M., Teixeira, E. d. M., Alves, L. L., Alves, É. A. R., Pascoal-Xavier, M. A., Santi, A. M. M., Oliveira, E., Guimarães, P. P. G., Teixeira-Carvalho, A., & Murta, S. M. F. (2024). Can letrozole be repurposed for the treatment of visceral leishmaniasis? Antimicrobial Agents and Chemotherapy, 68(11), e00756-00724. DOI: 10.1128/aac.00756-24.
Roberts, L., Janovy, J. Jr., & Nadler, S. (2012). Foundations of parasitology (9th ed.). McGraw-Hill Education.
Saravolatz, L. D., Bern, C., Adler-Moore, J., Berenguer, J., Boelaert, M., den Boer, M., Davidson, R. N., Figueras, C., Gradoni, L., & Kafetzis, D. A. (2006). Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases, 43(7), 917-924. DOI: 10.1086/507530.
Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A., & Charlier, P. (2008). The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiology Reviews, 32(2), 234-258. DOI: 10.1111/j.1574-6976.2008.00105.x.
Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2005). PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Research, 33(suppl 2), W363-W367. DOI: 10.1093/nar/gki481.
Sharma, P. C., Jain, A., Jain, S., Pahwa, R., & Yar, M. S. (2010). Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. Journal of Enzyme Inhibition and Medicinal Chemistry, 25(4), 577-589. DOI: 10.3109/14756360903373350.
Sheikh, S. Y., Hassan, F., Shukla, D., Bala, S., Faruqui, T., Akhter, Y., Khan, A. R., & Nasibullah, M. (2024). A review on potential therapeutic targets for the treatment of leishmaniasis. Parasitology International, 102863. DOI: 10.1016/j.parint.2024.102863.
Shmueli, M., & Ben-Shimol, S. (2024). Review of Leishmaniasis Treatment: Can We See the Forest through the Trees? Pharmacy, 12(1), 30. DOI: 10.3390/pharmacy12010030.
Sutanto, F., Konstantinidou, M., & Dömling, A. (2020). Covalent inhibitors: a rational approach to drug discovery. RSC Medicinal Chemistry, 11(8), 876-884. DOI: 10.1039/d0md00154f.
Thai, T., Salisbury, B. H., & Zito, P. M. (2023). Ciprofloxacin. In StatPearls [internet]. StatPearls Publishing.
The UniProt Consortium. (2021). UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research, 49(D1), D480–D489. https://doi.org/10.1093/nar/gkaa1100.
van Griensven, J., Dorlo, T. P., Diro, E., Costa, C., & Burza, S. (2024). The status of combination therapy for visceral leishmaniasis: An updated review. The Lancet Infectious Diseases, 24(1), e36-e46. DOI: 10.1016/S1473-3099(23)00353-5.
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Engineering, 8(2), 127-134. DOI: 10.1093/protein/8.2.127.
Wamai, R. G., Kahn, J., McGloin, J., & Ziaggi, G. (2020). Visceral leishmaniasis: a global overview. Journal of Global Health Science, 2(1). e3 https://doi.org/10.35500/jghs.2020.2.e3.
Worthen, D. (2017). Dictionary of pharmacy. Routledge. https://doi.org/10.1201/9781315274553.
Xander, P., Gonçalves, M. O., & Torrecilhas, A. C. (2024). Extracellular Vesicles Released by Trypanosoma cruzi and Leishmania spp.: Protozoan Parasite-Host Interaction Mechanism. Current Opinion in Physiology, 100792. https://doi.org/10.1016/j.cophys.2024.100792.
Yepes, A. F., Robledo, S. M., Quintero-Saumeth, J., & Cardona-Galeano, W. (2024). 3-styrylcoumarin scaffold-based derivatives as a new approach for leishmaniasis intervention: biological and molecular modeling studies. Journal of Parasitic Diseases, 48(1), 81-94. DOI: 10.1007/s12639-023-01639-x.
Yuan, M., Song, Z.-h., Ying, M.-d., Zhu, H., He, Q.-j., Yang, B., & Cao, J. (2020). N-myristoylation: from cell biology to translational medicine. Acta Pharmacologica Sinica, 41(8), 1005-1015. DOI: 10.1038/s41401-020-0388-4.
Zhao, C., & Ma, S. (2014). Recent advances in the discovery of N‐myristoyltransferase inhibitors. ChemMedChem, 9(11), 2425-2437. DOI: 10.1002/cmdc.201402174.
Zhou, Q., Zheng, Z., Yin, S., Duan, D., Liao, X., Xiao, Y., He, J., Zhong, J., Zeng, Z., & Su, L. (2024). Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism. Parasites & Vectors, 17(1), 288. DOI: 10.1186/s13071-024-06370-x.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Shoaib Alam, Adnan Shehzad, Bibi Ayesha, Hamid Ur Rahman
This work is licensed under a Creative Commons Attribution 4.0 International License.
